|
|
Article: Biotica Signs MTOR Inhibitor Deal With Wyeth For $195M.
- Article from:
- BIOWORLD Today
- Article date:
- October 6, 2006
- Author:
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Jennifer Boggs, Staff Writer
Biotica Technology Ltd. partnered a preclinical program targeting mTOR (mammalian target of rapamycin) in a potential $195 million deal with Wyeth Pharmaceuticals to develop compounds against multiple indications, including inflammatory diseases and cancer.
It marks the first major drug collaboration for Biotica, which was established about a decade ago as a technology-based spinout of Cambridge University. Three years ago, the company made the transformation into a drug discovery firm, and the Wyeth agreement is expected to be "the first of our significant licensing deals," said Mark Bodmer, Biotica's CEO.
...